Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.44 USD
Change Today -0.40 / -0.85%
Volume 633.1K
As of 3:47 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for novo-nordisk a/s-spons adr (NVO)

Year over year, Novo Nordisk A/S has been able to grow revenues from kr83.6B DKK to kr88.8B DKK. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold, SGA expenses and income tax expenses. All of these improvements led to a bottom line growth from kr25.2B DKK to kr26.5B DKK.
View Income Statement In U.S. Dollar
Currency in
Millions of Danish Krones
As of:Dec 31
Dec 31
Dec 31
Dec 31
4 Year
TOTAL REVENUES66,346.078,026.083,572.088,806.0
Cost of Goods Sold12,589.013,465.014,140.014,562.0
GROSS PROFIT53,757.064,561.069,432.074,244.0
Selling General & Admin Expenses, Total22,249.024,856.026,888.026,760.0
R&D Expenses9,628.010,897.011,733.013,162.0
Other Operating Expenses-494.0-666.0-682.0-770.0
OTHER OPERATING EXPENSES, TOTAL31,383.035,087.037,939.039,152.0
OPERATING INCOME22,374.029,474.031,493.035,092.0
Interest Expense-275.0-58.0-55.0-39.0
Interest and Investment Income274.0125.071.0101.0
Currency Exchange Gains (Loss)-322.0-1,529.01,146.0-381.0
Other Non-Operating Income (Expenses)-99.0-83.0-96.0-111.0
EBT, EXCLUDING UNUSUAL ITEMS21,952.027,929.032,559.034,662.0
Merger & Restructuring Charges-------600.0
Gain (Loss) on Sale of Investments-27.0-118.0-20.034.0
EBT, INCLUDING UNUSUAL ITEMS21,925.027,811.032,539.034,096.0
Income Tax Expense4,828.06,379.07,355.07,615.0
Earnings from Continuing Operations17,097.021,432.025,184.026,481.0
NET INCOME17,097.021,432.025,184.026,481.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS17,097.021,432.025,184.026,481.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS17,097.021,432.025,184.026,481.0

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $46.45 USD -0.39

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.50 USD -1.36
Biogen Idec Inc $417.49 USD -8.12
Bristol-Myers Squibb Co $65.01 USD -1.04
Eli Lilly & Co $68.38 USD -2.21
Reckitt Benckiser Group PLC 5,800 GBp -25.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NVO Industry Range
Price/Earnings 28.7x
Price/Sales 8.4x
Price/Book 18.6x
Price/Cash Flow 23.0x
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at